Taysha Gene Therapies is trading 7% higher at $4.74 in pre-market on October 9, with no new company-specific announcement identified to explain the move.
- Shares closed at $4.43 on October 8.
- Recent company news includes planned encore presentations of TSHA-102 Rett syndrome data and an inducement grant; neither is a new October 9 catalyst.
- Broader market indicators were mixed: the Nasdaq rose 0.79% and the S&P 500 rose 0.42%.